Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

IMVT

Immunovant Inc

Apr 18 • 04:00PM ET

28.32

Dollar change -0.11
Percentage change -0.39	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBR IWM VXF IWO IBB SCHA LABU VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.83	Insider Own	58.40%	Shs Outstand	130.33M	Perf Week	-7.81%
Market Cap	4.11B	Forward P/E	-	EPS next Y	-1.87	Insider Trans	-0.15%	Shs Float	60.45M	Perf Month	-8.91%
Income	-243.45M	PEG	-	EPS next Q	-0.43	Inst Own	46.30%	Short Float	14.92%	Perf Quarter	-30.14%
Sales	0.00M	P/S	-	EPS this Y	-4.71%	Inst Trans	5.05%	Short Ratio	7.81	Perf Half Y	-24.32%
Book/sh	4.68	P/B	6.05	EPS next Y	-4.20%	ROA	-41.70%	Short Interest	9.02M	Perf Year	79.47%
Cash/sh	4.76	P/C	5.96	EPS next 5Y	3.69%	ROE	-44.51%	52W Range	15.06 - 45.58	Perf YTD	-32.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-35.84%	52W High	-37.87%	Beta	0.74
Dividend TTM	-	Quick Ratio	22.14	Sales past 5Y	0.00%	Gross Margin	-	52W Low	88.05%	ATR (14)	1.54
Dividend Ex-Date	-	Current Ratio	22.14	EPS Y/Y TTM	-10.48%	Oper. Margin	0.00%	RSI (14)	33.86	Volatility	5.33% 5.02%
Employees	164	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.06	Target Price	50.87
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	27.65%	Payout	-	Rel Volume	1.06	Prev Close	28.43
Sales Surprise	-	EPS Surprise	33.09%	Sales Q/Q	-	Earnings	Feb 12 BMO	Avg Volume	1.15M	Price	28.32
SMA20	-8.96%	SMA50	-15.03%	SMA200	-11.02%	Trades		Volume	1,227,310	Change	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Initiated	Oppenheimer	Outperform	$50
Mar-13-24	Initiated	Goldman	Buy	$50
Feb-20-24	Initiated	JP Morgan	Overweight	$51
Feb-15-24	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Initiated	Deutsche Bank	Buy	$50
Oct-13-23	Upgrade	UBS	Neutral → Buy	$18 → $55
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$40
May-01-23	Initiated	BofA Securities	Buy	$26
Apr-25-23	Initiated	Citigroup	Buy	$28
Mar-31-23	Initiated	Piper Sandler	Overweight	$28
Mar-30-23	Initiated	Stifel	Buy	$28
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy	$30
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$10 → $27
Sep-26-22	Downgrade	UBS	Buy → Neutral	$7 → $5
Dec-08-21	Initiated	Wells Fargo	Equal Weight	$9
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral	$20 → $10
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform	$12 → $7
Jun-01-21	Downgrade	Stifel	Buy → Hold	$28 → $9
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Apr-17-24 12:00PM	What Makes Immunovant (IMVT) a New Buy Stock (Zacks) -6.48%
Mar-25-24 03:00PM	Wall Streets Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 04:45PM	Argenx, Immunovant Soar As Tourmaline Plummets On A Rival's Lackluster Test Results (Investor's Business Daily)
11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
07:04AM	Loading…
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 11:30AM	Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report? (Zacks)
Mar-12-24 07:30AM	Immunovant Awarded U.S. Patent for IMVT-1402 (GlobeNewswire)
Mar-08-24 09:35AM	Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks (Zacks)
Feb-26-24 03:04PM	3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 (InvestorPlace)
Feb-23-24 11:22PM	Immunovant Inc CFO Eva Barnett Sells 2,930 Shares (GuruFocus.com)
Feb-14-24 04:35AM	Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs (GuruFocus.com)
12:29AM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-13-24 07:26AM	Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus (Zacks)
Feb-12-24 07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 (GlobeNewswire)
02:38PM	Loading…
Feb-06-24 02:38PM	7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Jan-22-24 06:07AM	Should You Invest in Immunovant (IMVT)? (Insider Monkey)
Jan-19-24 04:39PM	3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-13-24 03:02AM	Immunovant Inc CFO Eva Barnett Sells 3,515 Shares (GuruFocus.com)
Jan-03-24 08:00AM	Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.33%
Dec-26-23 10:01AM	Immunovant (IMVT) Rose on Positive Clinical Trial (Insider Monkey) +6.53%
Dec-21-23 04:09PM	Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off (Investor's Business Daily) +8.07%
11:00AM	Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data (Zacks)
10:57AM	Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% (Benzinga)
06:49AM	Immunovant stakes claim for FcRn niche, posting midphase Graves' data and plotting next steps (FierceBiotech.com)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -12.84%
04:30PM	Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire)
Dec-19-23 10:16AM	11 Stocks Insiders and Billionaires Are Crazy About (Insider Monkey)
Dec-01-23 01:01AM	Here's Why Immunovant (IMVT) Outperformed in Q3 (Insider Monkey)
Nov-29-23 10:22AM	Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data (Zacks) +6.19%
07:00AM	Loading…
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire) +7.36%
07:00AM	Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
Nov-25-23 11:03AM	Immunovant Inc CEO Peter Salzmann Sells Over 16,000 Shares (GuruFocus.com)
Nov-14-23 12:30AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents) +6.62%
Nov-13-23 08:00AM	Immunovant to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-10-23 07:19AM	Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus (Zacks)
Nov-09-23 08:17AM	Immunovant Inc (IMVT) Reports Fiscal Q2 Results: R&D Investments Surge Amidst Clinical Progress (GuruFocus.com) -6.23%
07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023 (GlobeNewswire)
Oct-27-23 11:02PM	Insider Sell: Chief Legal Officer Mark Levine Sells 4,107 Shares of Immunovant Inc (GuruFocus.com)
Oct-13-23 09:50AM	Netflix downgraded, Applied Materials upgraded: Wall Street's top analyst calls (The Fly) +6.04%
Oct-11-23 11:01PM	CFO Eva Barnett Sells 4,557 Shares of Immunovant Inc (IMVT) (GuruFocus.com)
Oct-07-23 01:00AM	CEO Peter Salzmann Sells 5,239 Shares of Immunovant Inc (IMVT) (GuruFocus.com)
Oct-05-23 03:01AM	Sciences Roivant, Director and 10% Owner, Buys 1,526,316 Shares of Immunovant Inc (IMVT) (GuruFocus.com) +7.64%
Oct-02-23 04:52PM	Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -9.77%
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks)
Sep-27-23 11:41PM	Immunovant Announces Pricing of $450 Million Common Stock Financing (GlobeNewswire)
04:09PM	Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33% (Investor's Business Daily)
04:06PM	Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering (Investor's Business Daily)
12:25PM	Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% (Investor's Business Daily)
12:21PM	Why Immunovant Stock Is Bolting Higher Today (Motley Fool)
09:25AM	Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data (Zacks)
Sep-26-23 05:00PM	Immunovant Announces Proposed Offering of $300 Million of Common Stock (GlobeNewswire) +97.04%
04:13PM	Immunovant Doubles And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
04:06PM	Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations (Investopedia)
03:23PM	Why Shares of Immunovant Are Soaring on Tuesday (Motley Fool)
02:26PM	Rebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12 (TheStreet.com)
10:01AM	Immunovant Soars 73% And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
09:10AM	These 2 Biotech Stocks Are Bucking a Down Market Tuesday (Motley Fool)
06:00AM	Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire)
Sep-25-23 11:01PM	Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023 (GlobeNewswire)
Aug-17-23 09:31AM	15 Best-Performing Stocks in the Last 12 Months (Insider Monkey) -5.09%
Aug-12-23 08:25AM	We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate (Simply Wall St.)
Aug-11-23 11:20AM	Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus (Zacks)
Aug-10-23 07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023 (GlobeNewswire) +6.69%
Aug-09-23 06:26AM	Daily Vickers Top Buyers & Sellers for 08/09/2023 (Argus Research)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia)
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia)
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-29-23 01:42AM	Q4 2023 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Jun-21-23 11:30AM	Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-23-23 09:48AM	Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus (Zacks) -6.36%
06:05AM	Estimating The Intrinsic Value Of Immunovant, Inc. (NASDAQ:IMVT) (Simply Wall St.)
May-22-23 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023 (GlobeNewswire) +11.98%
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Feb-15-23 01:14PM	Immunovant Could Potentially Be An M&A Target, Writes Analyst (Benzinga)
Feb-03-23 07:00AM	Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022 (GlobeNewswire)
Dec-29-22 11:04AM	We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth (Simply Wall St.)
Dec-19-22 07:53AM	The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant (Zacks)
Dec-16-22 08:06AM	4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023 (Zacks)
Dec-15-22 09:40AM	Are Medical Stocks Lagging Immunovant (IMVT) This Year? (Zacks)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Nov-25-22 09:40AM	Are Medical Stocks Lagging BioVie (BIVI) This Year? (Zacks)
Nov-24-22 11:04AM	Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now (Zacks)
Nov-17-22 10:38AM	Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How (Zacks)
Nov-09-22 09:40AM	Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-07-22 01:34PM	Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus (Zacks) +5.15%
08:00AM	Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th (GlobeNewswire)
Nov-04-22 07:00AM	Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022 (GlobeNewswire)
Oct-20-22 01:56PM	Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab (Zacks)
Oct-09-22 10:57AM	While institutions invested in Immunovant, Inc. (NASDAQ:IMVT) benefited from last week's 63% gain, public companies stood to gain the most (Simply Wall St.)
Oct-06-22 03:52PM	Why Immunovant Stock Is Skyrocketing This Week (Motley Fool) +5.14%
Oct-04-22 08:45AM	Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock (GlobeNewswire) +23.98%
Sep-29-22 02:36PM	Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say (Benzinga) +12.32%
Sep-28-22 10:45AM	Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn (GlobeNewswire)
Sep-26-22 04:41PM	These 10 Stocks are Getting Crushed on Monday (Insider Monkey) -7.38%
Sep-21-22 08:00AM	Immunovant to Present at Roivant Investor Day on September 28th (GlobeNewswire)
Sep-09-22 08:00AM	Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th (GlobeNewswire)
Sep-07-22 07:11AM	UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab (GlobeNewswire)
06:30AM	Immunovant Announces Two New Development Programs for Batoclimab (GlobeNewswire)
Sep-06-22 09:26AM	Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why (Zacks) -10.15%

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Salzmann Peter	Chief Executive Officer	Apr 09 '24	Sale	31.18	4,807	149,882	1,086,958	Apr 10 04:14 PM
Barnett Eva Renee	Chief Financial Officer	Apr 09 '24	Sale	31.18	3,689	115,023	371,709	Apr 10 04:18 PM
Butchko Julia G.	Chief Development Officer	Apr 09 '24	Sale	31.18	1,053	32,833	461,742	Apr 10 04:16 PM
Salzmann Peter	Chief Executive Officer	Feb 22 '24	Sale	36.15	13,454	486,362	931,231	Feb 23 04:11 PM
Barnett Eva Renee	Chief Financial Officer	Feb 22 '24	Sale	36.15	2,930	105,920	320,420	Feb 23 04:21 PM
Macias William L.	Chief Medical Officer	Feb 22 '24	Sale	36.15	2,221	80,289	330,952	Feb 23 04:16 PM
Butchko Julia G.	Chief Development Officer	Feb 22 '24	Sale	36.15	2,146	77,578	407,817	Feb 23 04:14 PM
Levine Mark S.	Chief Legal Officer	Feb 22 '24	Sale	36.15	2,134	77,144	301,968	Feb 23 04:18 PM
Geffner Michael	Chief Medical Officer	Jan 26 '24	Sale	37.92	10,101	383,012	89,899	Jan 29 04:11 PM
Levine Mark S.	Chief Legal Officer	Jan 26 '24	Sale	37.92	3,027	114,778	304,102	Jan 29 04:12 PM
Macias William L.	Chief Medical Officer	Jan 18 '24	Sale	41.03	424	17,397	333,173	Jan 19 04:04 PM
Barnett Eva Renee	Chief Financial Officer	Jan 11 '24	Sale	41.83	3,515	147,023	323,350	Jan 12 04:34 PM
Salzmann Peter	Chief Executive Officer	Jan 05 '24	Sale	38.59	3,824	147,568	944,685	Jan 09 04:18 PM
Butchko Julia G.	Chief Development Officer	Jan 05 '24	Sale	38.59	1,297	50,051	409,963	Jan 09 04:20 PM
MIGAUSKY GEORGE V	Director	Dec 01 '23	Sale	39.73	12,700	504,567	109,808	Dec 05 04:25 PM
Fromkin Andrew J.	Director	Dec 01 '23	Sale	39.73	12,350	490,697	88,658	Dec 05 04:30 PM
Pande Atul	Director	Dec 01 '23	Sale	39.73	12,350	490,667	83,158	Dec 05 04:28 PM
Salzmann Peter	Chief Executive Officer	Nov 22 '23	Sale	32.78	16,217	531,581	948,509	Nov 24 02:55 PM
Barnett Eva Renee	Chief Financial Officer	Nov 22 '23	Sale	32.78	4,055	132,920	326,865	Nov 24 02:51 PM
Butchko Julia G.	Chief Development Officer	Nov 22 '23	Sale	32.78	3,265	107,024	411,260	Nov 24 02:47 PM
Macias William L.	Chief Medical Officer	Nov 22 '23	Sale	32.78	3,265	107,024	333,597	Nov 24 02:45 PM
Levine Mark S.	Chief Legal Officer	Nov 22 '23	Sale	32.78	3,252	106,598	307,129	Nov 24 02:41 PM
Levine Mark S.	Chief Legal Officer	Oct 25 '23	Sale	34.66	4,107	142,349	310,381	Oct 27 04:04 PM
Macias William L.	Chief Medical Officer	Oct 19 '23	Sale	36.80	530	19,504	336,862	Oct 20 04:06 PM
Barnett Eva Renee	Chief Financial Officer	Oct 10 '23	Sale	36.92	4,557	168,244	330,920	Oct 11 04:11 PM
Salzmann Peter	Chief Executive Officer	Oct 05 '23	Sale	36.24	5,239	189,887	964,726	Oct 06 05:10 PM
Butchko Julia G.	Chief Development Officer	Oct 05 '23	Sale	36.24	1,735	62,885	414,525	Oct 06 05:15 PM
Roivant Sciences Ltd.	Director	Oct 02 '23	Buy	38.00	1,526,316	58,000,008	79,805,331	Oct 04 05:15 PM
Salzmann Peter	Chief Executive Officer	Aug 30 '23	Sale	22.02	56,774	1,250,338	969,965	Sep 01 04:08 PM
Barnett Eva Renee	Chief Financial Officer	Aug 24 '23	Sale	20.30	14,386	292,036	335,477	Aug 25 05:03 PM
Macias William L.	Chief Medical Officer	Aug 24 '23	Sale	20.30	12,333	250,360	337,392	Aug 25 04:57 PM
Butchko Julia G.	Chief Development Officer	Aug 24 '23	Sale	20.30	12,333	250,360	416,260	Aug 25 05:00 PM
Levine Mark S.	Chief Legal Officer	Aug 24 '23	Sale	20.30	12,286	249,406	314,488	Aug 25 05:05 PM
Salzmann Peter	Chief Executive Officer	Aug 14 '23	Sale	21.42	103,058	2,207,178	1,026,739	Aug 16 04:11 PM
Salzmann Peter	Chief Executive Officer	Aug 07 '23	Sale	21.73	101,339	2,202,096	1,129,797	Aug 08 04:44 PM
Levine Mark S.	Chief Legal Officer	Jul 26 '23	Sale	21.63	3,917	84,725	326,774	Jul 27 04:33 PM
Barnett Eva Renee	Chief Financial Officer	Jul 19 '23	Sale	24.94	2,725	67,962	349,863	Jul 20 04:35 PM
Macias William L.	Chief Medical Officer	Jul 19 '23	Sale	24.94	426	10,624	349,725	Jul 20 04:37 PM
Salzmann Peter	Chief Executive Officer	Jul 12 '23	Sale	19.73	3,233	63,787	1,231,136	Jul 13 05:11 PM
Butchko Julia G.	Chief Development Officer	Jul 12 '23	Sale	19.73	1,470	29,003	428,593	Jul 13 05:10 PM
Levine Mark S.	Chief Legal Officer	Apr 25 '23	Sale	16.29	2,633	42,892	330,691	Apr 26 04:08 PM
Macias William L.	Chief Medical Officer	Apr 25 '23	Sale	16.29	509	8,292	350,151	Apr 26 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMVT

Immunovant Inc

Upgrade your FINVIZ experience